Finding Links Between Hot flASHes and CardioVascular Disease

Conditions

• Menopause-related Hot Flashes

Eligibility Criteria

Sex

FEMALE

Age

40 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• elinzanetant - reference formulation — DRUG
  elinzanetant 120 mg daily x 12 weeks
• placebo — DRUG
  placebo daily x 12 weeks

Study Details

The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?

Key Dates

Start date

Mar 1, 2026

Status verified

May 2026

Primary completion

Jun 30, 2029

Completion

Sep 30, 2029

Study Design

Enrollment

80 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: elinzanetant 120 mg daily for 12 weeks
• Placebo Comparator: Placebo daily for 12 weeks

Primary Outcome Measure

brachial artery flow mediated dilation [ Time Frame: 12 weeks ]

Central Contacts

• Kamila Bielawski
  617-724-3064
  [email protected]

Locations (2)

Find similar trials in Boston, MA